US FDA accepts Abbott's six-month 45-mg formulation of Lupron sNDA for review
Saturday, March 13, 2010 10:00 IST Abbott Park, Illinois
The US Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension)
